FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1874236485> ?p ?o ?g. }

• W1874236485 endingPage "R174" @default.
• W1874236485 startingPage "R174" @default.
• W1874236485 abstract "The objective of this work is to compare the adherence to therapy of patients receiving etanercept and infliximab during first tumour necrosis factor (TNF)-blocking treatment course in rheumatoid arthritis. Special emphasis is placed on potential predictors for treatment termination and the impact of concomitant methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs). Patients (n = 1,161) with active rheumatoid arthritis, not responding to at least two DMARDs including MTX starting etanercept or infliximab therapy for the first time, were included in a structured clinical follow-up protocol. Information on diagnosis, disease duration, previous and ongoing DMARDs, treatment start and termination, as well as cause of withdrawal was prospectively collected during the period of March 1999 through December 2004. Patients were divided into six groups according to TNF-blocking drugs and concomitant DMARDs. Five-year level (one-year) of adherence to therapy was 36% (69%) for patients receiving infliximab in combination with MTX compared with 65% (89%) for patients treated with etanercept and MTX (p < 0.001). Cox regression models showed that the risk for premature treatment termination of patients treated with infliximab was threefold higher than for etanercept (p < 0.001). Also, the regression analysis showed that patients receiving concomitant MTX had better treatment continuation than patients treated solely with TNF blockers (p < 0.001). Moreover, patients receiving concomitant MTX had superior drug survival than patients receiving other concomitant DMARDs (p < 0.010). The superior effect of MTX was associated primarily with fewer treatment terminations because of adverse events. In addition, the study identifies low C-reactive protein level, high age, elevated health assessment questionnaire score, and higher previous number of DMARDs as predictors of premature treatment termination. In summary, treatment with etanercept has higher adherence to therapy than treatment with infliximab. Concomitant MTX is associated with improved treatment continuation of biologics when compared with both TNF blockers as monotherapy and TNF blockers combined with other DMARDs." @default.
• W1874236485 created "2016-06-24" @default.
• W1874236485 creator A5007464106 @default.
• W1874236485 creator A5015705695 @default.
• W1874236485 creator A5015932797 @default.
• W1874236485 creator A5023940584 @default.
• W1874236485 date "2006-01-01" @default.
• W1874236485 modified "2023-10-17" @default.
• W1874236485 cites W1985763670 @default.
• W1874236485 cites W1995177703 @default.
• W1874236485 cites W1995228104 @default.
• W1874236485 cites W1996203160 @default.
• W1874236485 cites W1996472975 @default.
• W1874236485 cites W1997999969 @default.
• W1874236485 cites W2032121249 @default.
• W1874236485 cites W2091732273 @default.
• W1874236485 cites W2095056341 @default.
• W1874236485 cites W2096535957 @default.
• W1874236485 cites W2098767548 @default.
• W1874236485 cites W2111282166 @default.
• W1874236485 cites W2114270885 @default.
• W1874236485 cites W2116843833 @default.
• W1874236485 cites W2127682049 @default.
• W1874236485 cites W2129841863 @default.
• W1874236485 cites W2132180030 @default.
• W1874236485 cites W2152245204 @default.
• W1874236485 cites W2152721471 @default.
• W1874236485 cites W2319957449 @default.
• W1874236485 cites W2328587823 @default.
• W1874236485 cites W2335495110 @default.
• W1874236485 cites W2340084730 @default.
• W1874236485 cites W2418970185 @default.
• W1874236485 doi "https://doi.org/10.1186/ar2084" @default.
• W1874236485 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1794519" @default.
• W1874236485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17121678" @default.
• W1874236485 hasPublicationYear "2006" @default.
• W1874236485 type Work @default.
• W1874236485 sameAs 1874236485 @default.
• W1874236485 citedByCount "153" @default.
• W1874236485 countsByYear W18742364852012 @default.
• W1874236485 countsByYear W18742364852013 @default.
• W1874236485 countsByYear W18742364852014 @default.
• W1874236485 countsByYear W18742364852015 @default.
• W1874236485 countsByYear W18742364852016 @default.
• W1874236485 countsByYear W18742364852017 @default.
• W1874236485 countsByYear W18742364852018 @default.
• W1874236485 countsByYear W18742364852019 @default.
• W1874236485 countsByYear W18742364852020 @default.
• W1874236485 countsByYear W18742364852021 @default.
• W1874236485 countsByYear W18742364852022 @default.
• W1874236485 countsByYear W18742364852023 @default.
• W1874236485 crossrefType "journal-article" @default.
• W1874236485 hasAuthorship W1874236485A5007464106 @default.
• W1874236485 hasAuthorship W1874236485A5015705695 @default.
• W1874236485 hasAuthorship W1874236485A5015932797 @default.
• W1874236485 hasAuthorship W1874236485A5023940584 @default.
• W1874236485 hasBestOaLocation W18742364851 @default.
• W1874236485 hasConcept C126322002 @default.
• W1874236485 hasConcept C141071460 @default.
• W1874236485 hasConcept C17991360 @default.
• W1874236485 hasConcept C197934379 @default.
• W1874236485 hasConcept C198451711 @default.
• W1874236485 hasConcept C2777138892 @default.
• W1874236485 hasConcept C2777226972 @default.
• W1874236485 hasConcept C2777575956 @default.
• W1874236485 hasConcept C2779384505 @default.
• W1874236485 hasConcept C2781059491 @default.
• W1874236485 hasConcept C71924100 @default.
• W1874236485 hasConceptScore W1874236485C126322002 @default.
• W1874236485 hasConceptScore W1874236485C141071460 @default.
• W1874236485 hasConceptScore W1874236485C17991360 @default.
• W1874236485 hasConceptScore W1874236485C197934379 @default.
• W1874236485 hasConceptScore W1874236485C198451711 @default.
• W1874236485 hasConceptScore W1874236485C2777138892 @default.
• W1874236485 hasConceptScore W1874236485C2777226972 @default.
• W1874236485 hasConceptScore W1874236485C2777575956 @default.
• W1874236485 hasConceptScore W1874236485C2779384505 @default.
• W1874236485 hasConceptScore W1874236485C2781059491 @default.
• W1874236485 hasConceptScore W1874236485C71924100 @default.
• W1874236485 hasIssue "6" @default.
• W1874236485 hasLocation W18742364851 @default.
• W1874236485 hasLocation W18742364852 @default.
• W1874236485 hasLocation W18742364853 @default.
• W1874236485 hasLocation W18742364854 @default.
• W1874236485 hasOpenAccess W1874236485 @default.
• W1874236485 hasPrimaryLocation W18742364851 @default.
• W1874236485 hasRelatedWork W2033598112 @default.
• W1874236485 hasRelatedWork W2086963921 @default.
• W1874236485 hasRelatedWork W2090686119 @default.
• W1874236485 hasRelatedWork W2118015064 @default.
• W1874236485 hasRelatedWork W2312768097 @default.
• W1874236485 hasRelatedWork W2321747679 @default.
• W1874236485 hasRelatedWork W2352829214 @default.
• W1874236485 hasRelatedWork W2460286564 @default.
• W1874236485 hasRelatedWork W2552627355 @default.
• W1874236485 hasRelatedWork W79901769 @default.
• W1874236485 hasVolume "8" @default.
• W1874236485 isParatext "false" @default.

• next